IVERIC bio, Inc.
IVERIC bio, Inc., a leading biotechnology company headquartered in the United States, focuses on developing innovative therapies for retinal diseases. Founded in 2010, the company has made significant strides in the ophthalmology sector, particularly in the areas of gene therapy and pharmacological treatments. With a commitment to addressing unmet medical needs, IVERIC bio's core products include advanced gene therapies designed to target specific genetic conditions affecting vision. Their unique approach leverages cutting-edge science to enhance patient outcomes and improve quality of life. Recognised for its pioneering research and development, IVERIC bio has established a strong market position, contributing to advancements in the treatment of retinal disorders. The company continues to push the boundaries of innovation, aiming to transform the landscape of ocular health.
DitchCarbon Score
How does IVERIC bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
IVERIC bio, Inc.'s score of 50 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
IVERIC bio, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Astellas Pharma Inc., and any climate commitments or emissions data may be inherited from this parent organisation. As part of its climate strategy, IVERIC bio, Inc. aligns with initiatives from Astellas Pharma Inc., which may include targets set under the Science Based Targets initiative (SBTi) and disclosures to the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for IVERIC bio, Inc. have not been detailed. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and reducing their carbon footprints. While IVERIC bio, Inc. has not publicly committed to specific reduction initiatives or targets, it is essential to monitor their progress as part of Astellas Pharma Inc.'s broader environmental strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 108,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
IVERIC bio, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
